TWI910146B - 抗flt3抗體及組合物 - Google Patents

抗flt3抗體及組合物

Info

Publication number
TWI910146B
TWI910146B TW110113434A TW110113434A TWI910146B TW I910146 B TWI910146 B TW I910146B TW 110113434 A TW110113434 A TW 110113434A TW 110113434 A TW110113434 A TW 110113434A TW I910146 B TWI910146 B TW I910146B
Authority
TW
Taiwan
Prior art keywords
antibody
flt3
seq
antigen
amino acid
Prior art date
Application number
TW110113434A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200620A (zh
Inventor
特林 林德斯
瑪麗亞 卡爾森 梅蘭德
馬特奧 里瓦
米克爾 萬達 佩德森
蘭迪 威斯 韓森
Original Assignee
法商施維雅藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商施維雅藥廠 filed Critical 法商施維雅藥廠
Publication of TW202200620A publication Critical patent/TW202200620A/zh
Application granted granted Critical
Publication of TWI910146B publication Critical patent/TWI910146B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110113434A 2020-04-14 2021-04-14 抗flt3抗體及組合物 TWI910146B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009578P 2020-04-14 2020-04-14
US63/009,578 2020-04-14

Publications (2)

Publication Number Publication Date
TW202200620A TW202200620A (zh) 2022-01-01
TWI910146B true TWI910146B (zh) 2026-01-01

Family

ID=75530015

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110113434A TWI910146B (zh) 2020-04-14 2021-04-14 抗flt3抗體及組合物

Country Status (17)

Country Link
US (2) US12252539B2 (cg-RX-API-DMAC7.html)
EP (1) EP4136114A1 (cg-RX-API-DMAC7.html)
JP (1) JP7679399B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220167331A (cg-RX-API-DMAC7.html)
CN (1) CN115715297A (cg-RX-API-DMAC7.html)
AU (1) AU2021255884A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020683A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180188A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002833A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014520A2 (cg-RX-API-DMAC7.html)
IL (1) IL297269A (cg-RX-API-DMAC7.html)
MX (1) MX2022012919A (cg-RX-API-DMAC7.html)
PE (1) PE20230075A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552710A1 (cg-RX-API-DMAC7.html)
TW (1) TWI910146B (cg-RX-API-DMAC7.html)
WO (1) WO2021209495A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211267B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230075A1 (es) * 2020-04-14 2023-01-11 Servier Lab Anticuerpos anti-flt3 y composiciones
WO2024108163A2 (en) * 2022-11-18 2024-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd135 polypeptides
US20260217851A1 (en) * 2022-12-22 2026-07-30 The Medical College Of Wisconsin, Inc. Compositions that Target CD138 and CD3 and Methods of Making and Using the Same
CN122055383A (zh) * 2023-07-12 2026-05-15 费诺米人工智能公司 抗cthrc1 t细胞衔接体及其使用方法
CN118924724B (zh) * 2024-07-29 2025-11-04 湖南大学 一种用于治疗神经母细胞瘤的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770453A (zh) * 2009-12-23 2012-11-07 合成免疫股份有限公司 抗flt3抗体及其使用方法
US20170037149A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Antibody constructs for flt3 and cd3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186301B1 (en) 1993-09-08 2006-08-16 Imclone Systems, Inc. Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
WO2002066044A2 (en) 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
PE20241587A1 (es) 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Flt3に特異的な抗体およびその使用
EP3850010A1 (en) * 2018-09-11 2021-07-21 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved anti-flt3 antigen binding proteins
EP3902836B1 (en) * 2018-12-18 2026-03-25 Boehringer Ingelheim IO Canada Inc. Flt3 agonist antibodies and uses thereof
PE20230075A1 (es) * 2020-04-14 2023-01-11 Servier Lab Anticuerpos anti-flt3 y composiciones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770453A (zh) * 2009-12-23 2012-11-07 合成免疫股份有限公司 抗flt3抗体及其使用方法
US20170037149A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Antibody constructs for flt3 and cd3

Also Published As

Publication number Publication date
EP4136114A1 (en) 2023-02-22
KR20220167331A (ko) 2022-12-20
US12252539B2 (en) 2025-03-18
US20210317216A1 (en) 2021-10-14
JP7679399B2 (ja) 2025-05-19
ZA202211267B (en) 2026-05-27
TW202200620A (zh) 2022-01-01
CA3180188A1 (en) 2021-10-21
WO2021209495A1 (en) 2021-10-21
MX2022012919A (es) 2022-11-16
CL2022002833A1 (es) 2023-06-09
PE20230075A1 (es) 2023-01-11
US20250179195A1 (en) 2025-06-05
CO2022014520A2 (es) 2022-11-08
BR112022020683A2 (pt) 2022-11-29
IL297269A (en) 2022-12-01
CN115715297A (zh) 2023-02-24
AU2021255884A1 (en) 2022-11-17
JP2023522630A (ja) 2023-05-31
PH12022552710A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
JP7488323B2 (ja) 抗lag-3抗体および組成物
TWI780083B (zh) 抗pd-1抗體及組成物
TWI859319B (zh) 抗cd73抗體及組合物
JP6875385B2 (ja) 抗pd−1抗体および組成物
JP7679399B2 (ja) 抗flt3抗体及び組成物
JP2024520577A (ja) 抗nkg2a抗体及び組成物
TWI920062B (zh) 抗axl抗體及組合物
US20210214454A1 (en) Anti-cd40 antibodies and compositions
RU2836004C1 (ru) Антитела и композиции против flt3
EA052808B1 (ru) Антитела и композиции против flt3
HK40084729A (en) Anti-flt3 antibodies and compositions
HK40106092A (en) Anti-nkg2a antibodies and compositions
BR122025028949A2 (pt) Usos de: anticorpos anti-flt3, composição farmacêutica, molécula de ligaçâo biespecífica
EA046220B1 (ru) Анти-lag-3 антитела и их композиции